SCHEMBL7201577

SCHEMBL7201577

Cc1ccccc1OC1CCN(S(=O)(=O)C2CCNCC2(O)C(=O)NO)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 3/20 0.42
MMP13 P45452 3/20 0.42
ADAM10 O14672 1/20 0.42
MMP2 P08253 1/20 0.42
EPHX2 P34913 1/20 0.41
ALDH1A1 P00352 3/20 0.39
ADAM17 P78536 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
KMT2A Q03164 2/20 0.36
HSP90AB1 P08238 2/20 0.36
TOP2A P11388 2/20 0.36
FPR2 P25090 1/20 0.36
PROKR1 Q8TCW9 1/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
ADAMTS4 O75173 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
KCNH2 Q12809 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7202570 0.90 EPHX2 (0.41) MMP13ADAM10MMP2EPHX2ALDH1A1
SCHEMBL7201026 0.89 HTR2C (0.48) EPHX2HTR2AHTR2CKCNH2
SCHEMBL7203079 0.89 HTR2C (0.47) MMP13ADAM10MMP2ALDH1A1L3MBTL1
SCHEMBL7199648 0.86 HTR2C (0.44) MMP13MMP2EPHX2ADAM17FPR2
SCHEMBL7200991 0.84 MMP13 (0.43) MMP1MMP13MMP2EPHX2ADAM17
SCHEMBL7205529 0.84 MMP1 (0.45) MMP1MMP13ADAM10MMP2EPHX2
SCHEMBL7202359 0.84 MMP13 (0.61) MMP1MMP13ADAM10MMP2EPHX2
SCHEMBL7205516 0.83 ADAM10 (0.51) MMP1MMP13ADAM10MMP2ADAM17
SCHEMBL7200949 0.83 MMP13 (0.45) MMP1MMP13EPHX2ALDH1A1ADAM17
SCHEMBL7201546 0.82 SMN1; SMN2 (0.48) MMP1MMP13MMP2EPHX2FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP1 8/4885MMP13 4/4885ADAM10 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.